Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
Sign Up to like & getrecommendations! Published in 2021 at "Iranian Journal of Microbiology"
DOI: 10.18502/ijm.v13i6.8080
Abstract: Background and Objectives: Imipenem/relebactam (IMP/R) is a newly FDA approved β-lactam/β-lactamase inhibitor combination. Relebactam ability to restore IMP activity could differ according to the cause of imipenem non-susceptibility. Therefore, we investigated the in-vitro activity of… read more here.
Keywords: imp; imipenem non; activity; non susceptibility ... See more keywords